RxDoctor Payments Data

Mark Shelnutt, MD

Internal Medicine · Springdale, ARNPI 1508177957

Payments from drug & device makers

$960in general payments, 2019–2025

Across 57 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$142
  • GSK$98
  • Johnson & Johnson$87
  • AstraZeneca$86
  • Amgen$86
  • Exact Sciences$69
  • plus $391 from 9 others

What the payments were for

  • Food & beverage$960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$960 in reported general payments places this provider in the 70th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$106,121
Medicare patients
285
Services billed
1,771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5014$199,260
MounjaroTirzepatide139$165,092
OzempicSemaglutide91$101,684
EliquisApixaban60$61,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$52,056
JardianceEmpagliflozin29$44,359
Tresiba Flextouch U-200Insulin Degludec34$37,041
LinzessLinaclotide20$32,166
FarxigaDapagliflozin Propanediol24$23,451
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$20,409
RexultiBrexpiprazole12$19,753
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,591
MyrbetriqMirabegron12$10,600
Ajovy AutoinjectorFremanezumab-Vfrm12$8,654
Spiriva RespimatTiotropium Bromide14$8,534

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Eliquis$142$260,33174 claims
Lilly USA, LLCMounjaro, Humalog$13$166,573150 claims
Novo NordiskOzempic$48$101,68491 claims
GSKTrelegy Ellipta$98$52,05667 claims
AstraZenecaFarxiga, Breztri Aerosphere$86$35,04241 claims
AbbVieLinzess, Synthroid$69$33,43342 claims
Astellas Pharma US IncMyrbetriq$57$10,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →